

1646
IFW



WSP/SLR:dm 12/20/04 6235-62514-01 337747

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Matsumoto et al.

Application No. 10/088,726

Filed: October 1, 2002

Confirmation No. 6930

For: NOVEL GUANOSINE TRIPHOSPHATE-BINDING PROTEIN-COUPLED RECEPTORS, GENES THEREOF AND PRODUCTION AND USE OF SAME


Examiner: Nirmal S. Basi

Art Unit: 1646

Attorney Reference No. 6235-62514-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney for Applicant(s) 

Date Mailed December 20, 2004

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are two English-language documents. Applicants respectfully request that these documents be listed as a reference cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS.

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby states that each item of information contained in the IDS filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. As a result, no fee should be required to file this IDS.


If the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

By


Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6235-62514-01
Application Number	10/088,726
Filing Date	October 1, 2002
First Named Inventor	Matsumoto
Art Unit	1646
Examiner Name	Nirmal S. Basi

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 01/36473 A2	25.05.2001	Pharmacia & Upjohn Company
		WIPO	WO 01/036473 A3	11.07.2002	Pharmacia & Upjohn Company

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.